September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Meibomian gland dysfunction model in hairless mice bred under special diet limiting lipid content
Author Affiliations & Notes
  • hideki miyake
    Research and Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan
    Department of Medical Bioengineering, Division of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama, Japan
  • Tomoko Oda
    Research and Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan
  • Osamu Katsuta
    Research and Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan
  • masaharu seno
    Department of Medical Bioengineering, Division of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University, Okayama, Japan
  • Masatsugu Nakamura
    Research and Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan
  • Footnotes
    Commercial Relationships   hideki miyake, Santen Pharmaceutical Co., Ltd. (E), Santen Pharmaceutical Co., Ltd. (P); Tomoko Oda, Santen Pharmaceutical Co., Ltd. (E), Santen Pharmaceutical Co., Ltd. (P); Osamu Katsuta, Santen Pharmaceutical Co., Ltd. (E); masaharu seno, None; Masatsugu Nakamura, Santen Pharmaceutical Co., Ltd. (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5704. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      hideki miyake, Tomoko Oda, Osamu Katsuta, masaharu seno, Masatsugu Nakamura; Meibomian gland dysfunction model in hairless mice bred under special diet limiting lipid content. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5704.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : A novel meibomian gland dysfunction (MGD) model should help us understand pathophysiology in MGD, and evaluate Azithromycin ophthalmic solution (Azithromycin). In this study the MGD was induced in HR-1 hairless mice to by feeding a special diet limiting lipids (HR-AD).

Methods : Male HR-1 hairless mice were bred with HR-AD diet for 16 weeks. Development of MGD was assessed by histopathology at the intervals of 4 weeks. Lid margin of the mice were observed by slit lamp examination. After the cessation of HR-AD diet, the mice were bred by normal diet to regain normal condition. We evaluated the effect of topically applied Azithromycin on the plugged orifice using this model.

Results : After 4 weeks of HR-AD diet, histopathology showed thick hyperkeratinization of the ductal epithelium in the meibomian gland. After 8 weeks, the ductal hyperkeratinization lead to extreme loss of acini followed by atrophy of the gland. Slit lamp examination revealed markedly plugged orifice, telangiectasia around the orifices and toothpaste like meibum compared with those of the normal eyelid. The cessation of feeding HR-AD recovered of both MGD signs and the atrophy of acini. Azithromycin significantly decreased the number of plugged orifices and histopathologically recovered the atrophy.

Conclusions : We developed novel model mimicking human MGD symptoms in HR-1 hairless mice feeding HR-AD diet. Azithromycin demonstrated therapeutic improvement of plugging and atrophy of acini in the model. This MGD model could be useful to evaluate the pathophysiological efficacy of drug candidates.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×